AU2005286763A1 - Variants and chemically-modified variants of phenylalanine ammonia-lyase - Google Patents

Variants and chemically-modified variants of phenylalanine ammonia-lyase Download PDF

Info

Publication number
AU2005286763A1
AU2005286763A1 AU2005286763A AU2005286763A AU2005286763A1 AU 2005286763 A1 AU2005286763 A1 AU 2005286763A1 AU 2005286763 A AU2005286763 A AU 2005286763A AU 2005286763 A AU2005286763 A AU 2005286763A AU 2005286763 A1 AU2005286763 A1 AU 2005286763A1
Authority
AU
Australia
Prior art keywords
pal
protein
peg
activity
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005286763A
Other languages
English (en)
Inventor
Paul A. Fitzpatrick
Alejandra Gamez
Robert Heft
Emil Kakkis
Woomi Kim
Dan Oppenheimer
Marianne G. Patch
Raymond C. Stevens
Mary Straub
Lin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Biomarin Pharmaceutical Inc
Original Assignee
Scripps Research Institute
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, Biomarin Pharmaceutical Inc filed Critical Scripps Research Institute
Publication of AU2005286763A1 publication Critical patent/AU2005286763A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2005286763A 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase Abandoned AU2005286763A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61077004P 2004-09-17 2004-09-17
US60/610,770 2004-09-17
US65195005P 2005-02-09 2005-02-09
US60/651,950 2005-02-09
PCT/US2005/033895 WO2006034373A2 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Publications (1)

Publication Number Publication Date
AU2005286763A1 true AU2005286763A1 (en) 2006-03-30

Family

ID=36090659

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005286763A Abandoned AU2005286763A1 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Country Status (6)

Country Link
US (1) US7553653B2 (https=)
EP (1) EP1814984A2 (https=)
JP (1) JP2008513027A (https=)
AU (1) AU2005286763A1 (https=)
CA (1) CA2580679A1 (https=)
WO (1) WO2006034373A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
WO2008128049A2 (en) 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
CA2755047C (en) * 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
ES2582459T3 (es) 2010-02-04 2016-09-13 Biomarin Pharmaceutical Inc. Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014018822A2 (en) * 2012-07-26 2014-01-30 Casa Luker S.A. Methods for increasing the production of phenolic compounds from theobroma cacao
KR102218930B1 (ko) 2013-04-18 2021-02-23 코덱시스, 인코포레이티드 조작된 페닐알라닌 암모니아 리아제 폴리펩티드
WO2015161019A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
SG11202105668PA (en) 2018-12-14 2021-06-29 Codexis Inc Engineered tyrosine ammonia lyase
CA3154817A1 (en) * 2019-10-17 2021-04-22 James Nolan Pegylated kynureninase enzymes and uses thereof for the treatment of cancer
WO2021158686A1 (en) 2020-02-04 2021-08-12 Codexis, Inc. Engineered leucine decarboxylases
CN115298308A (zh) * 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
EP4204554A4 (en) 2020-08-28 2024-08-21 Codexis, Inc. MODIFIED PROTEASE VARIANTS
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
CN118475692A (zh) 2021-11-01 2024-08-09 森蒂斯生物公司 工程化亮氨酸脱羧酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
US20250108095A1 (en) * 2023-09-28 2025-04-03 Aperiam Bio, Inc. Degradation of toxins in vivo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DK75593D0 (https=) * 1993-06-25 1993-06-25 Novo Nordisk As
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
EP1476563B1 (en) * 2002-02-26 2008-09-17 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
US20080124275A1 (en) * 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)

Also Published As

Publication number Publication date
US20070048855A1 (en) 2007-03-01
WO2006034373A3 (en) 2006-11-02
WO2006034373A8 (en) 2006-08-10
WO2006034373A2 (en) 2006-03-30
WO2006034373A9 (en) 2006-05-11
JP2008513027A (ja) 2008-05-01
CA2580679A1 (en) 2006-03-30
EP1814984A2 (en) 2007-08-08
US7553653B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
AU2005286763A1 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
JP7336178B2 (ja) 治療における使用のための新規のＴＮＦα構造
WO2001083769A2 (en) Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis
WO2003012089A2 (en) Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
AU6960696A (en) Crystalline zap family proteins
WO2001085748A2 (en) Designing modulators for glycosyltransferases
EP2665813A2 (en) Crystal structure of a type ib p-type atpase
WO2004106506A2 (en) Crystallographic structure of trypanosoma cruzi proline racemase (tcpraca) and uses thereof
MX2008015580A (es) Metodos para identificar imitadores de toxina de araña especificos para insectos.
CN101228270A (zh) 人可溶性腺苷酸环化酶的晶体结构
KR101421089B1 (ko) 대장암에 특이적인 항암 활성을 갖는 신규 펩타이드, 이를 포함하는 ｎｄｒｇ２ 결정체 및 이의 용도
AU770150B2 (en) Three-dimensional model of a FC epsilon receptor alpha chain and uses thereof
WO2009076621A1 (en) High resolution structures of acidic mammalian chitinases and uses thereof
AU2007204226B2 (en) ACE N-domain crystal
WO2012037150A1 (en) Crystal structures of o-glcnac transferase and uses thereof
CN1993379A (zh) 抗il－13抗体、抗il－13抗体的晶体以及包含它们的复合物
WO2009141455A1 (en) Immunogenic polypeptides that mimic the surface polysaccharide o-antigen from serotype 2a shigella flexneri, method for obtaining the same, and their use in vaccine and diagnostic compositions
WO2004078910A2 (en) Identifying inhibitors of type ii isopentenyl diphosphate: dimethylallyl diphosphate isomerase
AU5660900A (en) Crystalline zap family proteins
WO2004072276A1 (en) Crystal structure of 2-c-methyl-d-erythritol 4-phosphate synthase in complex with inhibitors
MXPA05012919A (en) CRYSTALLOGRAPHIC STRUCTURE OF TcPRACA AND USES THEREFOR
EP1546315A1 (en) Atomic structure of the catalytic domain for use in designing and identifying inhibitors of zap-70 kinase
HK1120557A (en) Crystal structure of human soluble adenylate cyclase
CA2982386A1 (en) Crystal structure of staphylococcus aureus autolysin e, method of producing the crystal and its use in screening methods

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application